117 results on '"Sievers, Richard E."'
Search Results
102. Validation of the Wall Motion Score for Assessing Left Ventricular Dysfunction in Mice with Myocardial Infarction.
- Author
-
Zhang, Yan, Takagawa, Junya, Sievers, Richard E, Khan, Muhammad, Springer, Matthew L, Foster, Elyse, and Yeghiazarians, Yerem
- Published
- 2006
103. Histological Assessment of Myocardial Infarct Size in the Mouse Chronic Infarction Model: Infarct Length Measurement Is More Accurate than Infarct Area Measurement.
- Author
-
Takagawa, Junya, Zhang, Yan, Sievers, Richard E, Kapasi, Neel K, Wong, Maelene L, Yeghiazarians, Yerem, Lee, Randall J, Grossman, William, and Springer, Matthew L
- Published
- 2006
104. Closed-Chest Cell Injections into Mouse Myocardium Guided by High-Resolution Echocardiography.
- Author
-
Springer, Matthew L, Sievers, Richard E, Viswanathan, Mohan N, Yee, Michael S, Foster, Elyse, Grossman, William, and Yeghiazarians, Yerem
- Published
- 2005
105. 933. Closed-Chest Cell Injections into Mouse Myocardium Guided by High-Resolution Echocardiography
- Author
-
Springer, Matthew L., Sievers, Richard E., Viswanathan, Mohan N., Yee, Michael S., Foster, Elyse, Grossman, William, and Yeghiazarians, Yerem
- Subjects
- *
ECHOCARDIOGRAPHY - Abstract
An abstract of the article "Closed-Chest Cell Injections into Mouse Myocardium Guided by High-Resolution Echocardiography," by Matthew L. Springer and colleagues is presented.
- Published
- 2005
- Full Text
- View/download PDF
106. Testosterone, but not estradiol, attenuates acetyicholine-induced relaxation of tobacco smoke-exposed hypercholesterolemic rabbit aorta
- Author
-
Hutchison, Stuart J., Chou, Tony M., Sievers, Richard E., Sudhir, Krishnankutty, Chatterjee, Kanu, Deedwania, Prakash C., and Parmley, William W.
- Published
- 1996
- Full Text
- View/download PDF
107. Antioxidant dietary suppelementation with vitamin E decreased atherosclerosis and cellular proliferation in lipid-fed rabbits exposed to passive smoking
- Author
-
Zhu, Bo-qing, Sun, Yi-ping, Sievers, Richard E., Norkus, Edward P., Glantz, Stanton A., Wang, Bing-yin, Cooke, John P., Parmley, William W., and Deedwania, Prakash C.
- Published
- 1996
- Full Text
- View/download PDF
108. Overexpression of inducible heat shock protein (HSP)72 in transgenic mice decreases infarct size
- Author
-
Hutter, Jonathan J., Mearil, Ruben, Tam, Eunice K.W., Sievers, Richard E., Dillmann, Wolfgang H., and L. Wolfe, Christopher
- Published
- 1996
- Full Text
- View/download PDF
109. Discrete microstructural cues for the attenuation of fibrosis following myocardial infarction.
- Author
-
Pinney, James R., Du, Kim T., Ayala, Perla, Qizhi Fang, Sievers, Richard E., Chew, Patrick, Delrosario, Lawrence, Lee, Randall J., and Desai, Tejal A.
- Subjects
- *
CYSTIC fibrosis , *MICROSTRUCTURE , *PHOTOLITHOGRAPHY , *TISSUE engineering , *LABORATORY rats ,MYOCARDIAL infarction-related mortality - Abstract
Chronic fibrosis caused by acute myocardial infarction (MI) leads to increased morbidity and mortality due to cardiac dysfunction. We have developed a therapeutic materials strategy that aims to mitigate myocardial fibrosis by utilizing injectable polymeric microstructures to mechanically alter the microenvironment. Polymeric microstructures were fabricated using photolithographic techniques and studied in a three-dimensional culture model of the fibrotic environment and by direct injection into the infarct zone of adult rats. Here, we show dose-dependent down-regulation of expression of genes associated with the mechanical fibrotic response in the presence of microstructures. Injection of this microstructured material into the infarct zone decreased levels of collagen and TGF-β, increased elastin deposition and vascularization in the infarcted region, and improved functional outcomes after six weeks. Our results demonstrate the efficacy of these discrete anti-fibrotic microstructures and suggest a potential therapeutic materials approach for combatting pathologic fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
110. Pleiotrophin Gene Therapy for Peripheral Ischemia: Evaluation of Full-Length and Truncated Gene Variants.
- Author
-
Fang, Qizhi, Mok, Pamela Y., Thomas, Anila E., Haddad, Daniel J., Saini, Shereen A., Clifford, Brian T., Kapasi, Neel K., Danforth, Olivia M., Usui, Minako, Ye, Weisheng, Luu, Emmy, Sharma, Rikki, Bartel, Maya J., Pathmanabhan, Jeremy A., Ang, Andrew A. S., Sievers, Richard E., Lee, Randall J., and Springer, Matthew L.
- Subjects
- *
PLEIOTROPHIN , *GENE therapy , *ISCHEMIA , *GROWTH factors , *NEOPLASTIC cell transformation , *LABORATORY mice , *GENE expression , *CARDIOVASCULAR system , *MYOBLASTS - Abstract
Pleiotrophin (PTN) is a growth factor with both pro-angiogenic and limited pro-tumorigenic activity. We evaluated the potential for PTN to be used for safe angiogenic gene therapy using the full length gene and a truncated gene variant lacking the domain implicated in tumorigenesis. Mouse myoblasts were transduced to express full length or truncated PTN (PTN or T-PTN), along with a LacZ reporter gene, and injected into mouse limb muscle and myocardium. In cultured myoblasts, PTN was expressed and secreted via the Golgi apparatus, but T-PTN was not properly secreted. Nonetheless, no evidence of uncontrolled growth was observed in cells expressing either form of PTN. PTN gene delivery to myocardium, and non-ischemic skeletal muscle, did not result in a detectable change in vascularity or function. In ischemic hindlimb at 14 days post-implantation, intramuscular injection with PTN-expressing myoblasts led to a significant increase in skin perfusion and muscle arteriole density. We conclude that (1) delivery of the full length PTN gene to muscle can be accomplished without tumorigenesis, (2) the truncated PTN gene may be difficult to use in a gene therapy context due to inefficient secretion, (3) PTN gene delivery leads to functional benefit in the mouse acute ischemic hindlimb model. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
111. 453. Injectionof Different Adult Cell Types into Mouse Myocardium Three Days after Myocardial Infarction Using a Novel Echo-Guided Technique Improves Cardiac Function.
- Author
-
Yan Zhang, Takagawa, Junya, Sievers, Richard E., Wong, Maelene L., Heiss, Christian, Viswanathan, Mohan N., Kapasi, Neel K., Jianqin Ye, Foster, Elyse, Grossman, William, Springer, Matthew L., and Yeghiazarians, Yerem
- Subjects
- *
MYOCARDIUM , *STEM cell transplantation , *MYOCARDIAL infarction , *BONE marrow cells , *MICE - Abstract
Objective: Myocardial regeneration based on stem cell transplantation has emerged as a potential therapeutic approach toward replacing myocardial scar with functioning contractile tissue after myocardial infarction (MI). Considerable interest has focused on bone marrow cells (BMCs) and endothelial progenitor cells (EPCs) because they appear successful in attenuating remodeling following acute MI. However, preclinical experiments toward this goal have been limited to treatment within hours of an MI, in contrast to human trials, in which cell treatment has been performed several days later after patient stabilization and autologous cell harvesting. We sought to compare the therapeutic effects of different types of putative stem and progenitor cells in a mouse model of MI using a novel closed-chest echo-guided injection approach to deliver cells 3 days after infarction.Methods: MI was surgically induced in adult male mice by performing a mid-LAD ligation. Closed-chest echo-guided injection of cells (5 x 105 in 5 ul or saline control (HBSS) into myocardium at the peri-infarct border zone was performed at day 3 post-MI in the following groups (n=8/group): mouse BMCs (mBMCs) into C57BL/6 mice, human BMCs into immunodeficient SCID mice, mBMCs into SCID, human EPCs into SCID, and HBSS into both C57BL/6 and SCID as controls. Echocardiography was accomplished in a blinded manner with a Vevo 660 system (VisualSonics, Toronto) at baseline, 2 days post-MI (before injection), and at day 28 post-MI.Results: Left ventricular ejection fraction (LVEF) was uniformly reduced from 57.2+/-4.0% to 38.4+/-3.7% (p<0.0001) after MI in all groups. Mice injected with mBMCs showed the best effect with significant improvement in global LVEF (37.8+/-2.3% vs 44.4+/-6.3%, p=0.03), and in regional wall motion index in the infarct area (1.79+/-0.21 vs 1.4+/-0.29, p=0.02) at day 28, and there was a tendency toward less dilation of cardiac dimensions compared with that before injection. The global systolic function of the treatment group injected with mBMCs was significantly better preserved than that of its corresponding control group (44.4+/-6.3% vs 31.1+/-10.4%, p<0.0005). Human EPC injection showed a non-significant trend toward improvement of LVEF and less LV dilation, while the LVEF of its corresponding control group continued to decrease, resulting in a significant difference between the EPC group and its controls at day 28 (41.5 +/-4.3 vs 32.1+/-6.3, p<0.0005).Conclusions: Unfractionated mouse bone marrow cells attenuated ventricular remodeling and partially preserved LV function when delivered several days after surgically-induced MI. However, injection of different cell types affects LV function to varying extents. The percutaneous echo-guided injection approach made it possible to assess therapeutic cell implantation at a clinically relevant time after MI in a mouse model.Molecular Therapy (2006) 13, S175–S175; doi: 10.1016/j.ymthe.2006.08.521 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
112. Injectable hyaluronic acid based microrods provide local micromechanical and biochemical cues to attenuate cardiac fibrosis after myocardial infarction.
- Author
-
Le LV, Mohindra P, Fang Q, Sievers RE, Mkrtschjan MA, Solis C, Safranek CW, Russell B, Lee RJ, and Desai TA
- Subjects
- Animals, Cell Line, Fibrosis therapy, Humans, Mice, Myocardial Infarction pathology, Myocardium pathology, Rats, Rats, Sprague-Dawley, Cellular Reprogramming Techniques, Hyaluronic Acid, Microspheres, Myocardial Infarction therapy, Tissue Engineering
- Abstract
Repairing cardiac tissue after myocardial infarction (MI) is one of the most challenging goals in tissue engineering. Following ischemic injury, significant matrix remodeling and the formation of avascular scar tissue significantly impairs cell engraftment and survival in the damaged myocardium. This limits the efficacy of cell replacement therapies, demanding strategies that reduce pathological scarring to create a suitable microenvironment for healthy tissue regeneration. Here, we demonstrate the successful fabrication of discrete hyaluronic acid (HA)-based microrods to provide local biochemical and biomechanical signals to reprogram cells and attenuate cardiac fibrosis. HA microrods were produced in a range of physiological stiffness and shown to degrade in the presence of hyaluronidase. Additionally, we show that fibroblasts interact with these microrods in vitro, leading to significant changes in proliferation, collagen expression and other markers of a myofibroblast phenotype. When injected into the myocardium of an adult rat MI model, HA microrods prevented left ventricular wall thinning and improved cardiac function at 6 weeks post infarct., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
113. One Minute of Marijuana Secondhand Smoke Exposure Substantially Impairs Vascular Endothelial Function.
- Author
-
Wang X, Derakhshandeh R, Liu J, Narayan S, Nabavizadeh P, Le S, Danforth OM, Pinnamaneni K, Rodriguez HJ, Luu E, Sievers RE, Schick SF, Glantz SA, and Springer ML
- Subjects
- Animals, Coronary Circulation drug effects, Female, Nitric Oxide metabolism, Nitroglycerin pharmacology, Peripheral Vascular Diseases etiology, Peripheral Vascular Diseases physiopathology, Rats, Sprague-Dawley, Time Factors, Vasodilation drug effects, Vasodilator Agents pharmacology, Air Pollution adverse effects, Endothelium, Vascular drug effects, Marijuana Smoking adverse effects, Smoke adverse effects
- Abstract
Background: Despite public awareness that tobacco secondhand smoke (SHS) is harmful, many people still assume that marijuana SHS is benign. Debates about whether smoke-free laws should include marijuana are becoming increasingly widespread as marijuana is legalized and the cannabis industry grows. Lack of evidence for marijuana SHS causing acute cardiovascular harm is frequently mistaken for evidence that it is harmless, despite chemical and physical similarity between marijuana and tobacco smoke. We investigated whether brief exposure to marijuana SHS causes acute vascular endothelial dysfunction., Methods and Results: We measured endothelial function as femoral artery flow-mediated dilation (FMD) in rats before and after exposure to marijuana SHS at levels similar to real-world tobacco SHS conditions. One minute of exposure to marijuana SHS impaired FMD to a comparable extent as impairment from equal concentrations of tobacco SHS, but recovery was considerably slower for marijuana. Exposure to marijuana SHS directly caused cannabinoid-independent vasodilation that subsided within 25 minutes, whereas FMD remained impaired for at least 90 minutes. Impairment occurred even when marijuana lacked cannabinoids and rolling paper was omitted. Endothelium-independent vasodilation by nitroglycerin administration was not impaired. FMD was not impaired by exposure to chamber air., Conclusions: One minute of exposure to marijuana SHS substantially impairs endothelial function in rats for at least 90 minutes, considerably longer than comparable impairment by tobacco SHS. Impairment of FMD does not require cannabinoids, nicotine, or rolling paper smoke. Our findings in rats suggest that SHS can exert similar adverse cardiovascular effects regardless of whether it is from tobacco or marijuana., (© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.)
- Published
- 2016
- Full Text
- View/download PDF
114. Brief exposure to secondhand smoke reversibly impairs endothelial vasodilatory function.
- Author
-
Pinnamaneni K, Sievers RE, Sharma R, Selchau AM, Gutierrez G, Nordsieck EJ, Su R, An S, Chen Q, Wang X, Derakhshandeh R, Aschbacher K, Heiss C, Glantz SA, Schick SF, and Springer ML
- Subjects
- Animals, Dilatation, Pathologic, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Femoral Artery physiopathology, Humans, Rats, Rats, Sprague-Dawley, Time Factors, Endothelium, Vascular drug effects, Endothelium, Vascular physiopathology, Tobacco Smoke Pollution adverse effects
- Abstract
Introduction: We sought to determine the effects of brief exposures to low concentrations of tobacco secondhand smoke (SHS) on arterial flow-mediated dilation (FMD, a nitric oxide-dependent measure of vascular endothelial function), in a controlled animal model never before exposed to smoke. In humans, SHS exposure for 30 min impairs FMD. It is important to gain a better understanding of the acute effects of exposure to SHS at low concentrations and for brief periods of time., Methods: We measured changes in FMD in rats exposed to a range of real-world levels of SHS for durations of 30 min, 10 min, 1 min, and 4 breaths (roughly 15 s)., Results: We observed a dose-response relationship between SHS particle concentration over 30 min and post-exposure impairment of FMD, which was linear through the range typically encountered in smoky restaurants and then saturated at higher concentrations. One min of exposure to SHS at moderate concentrations was sufficient to impair FMD., Conclusions: Brief SHS exposure at real-world levels reversibly impairs FMD. Even 1 min of SHS exposure can cause reduction of endothelial function.
- Published
- 2014
- Full Text
- View/download PDF
115. Pharmacological inhibition of S-nitrosoglutathione reductase improves endothelial vasodilatory function in rats in vivo.
- Author
-
Chen Q, Sievers RE, Varga M, Kharait S, Haddad DJ, Patton AK, Delany CS, Mutka SC, Blonder JP, Dubé GP, Rosenthal GJ, and Springer ML
- Subjects
- Administration, Oral, Aldehyde Oxidoreductases metabolism, Animals, Antihypertensive Agents administration & dosage, Blood Pressure drug effects, Cells, Cultured, Disease Models, Animal, Dose-Response Relationship, Drug, Endothelium, Vascular enzymology, Endothelium, Vascular physiopathology, Enzyme Inhibitors administration & dosage, Femoral Artery enzymology, Femoral Artery physiopathology, Humans, Hypertension enzymology, Hypertension etiology, Hypertension pathology, Hypertension physiopathology, Injections, Intravenous, Kidney drug effects, Kidney pathology, Mice, Nitric Oxide metabolism, Nitric Oxide Synthase Type III antagonists & inhibitors, Nitric Oxide Synthase Type III metabolism, Rats, Rats, Inbred Dahl, Rats, Sprague-Dawley, Sodium Chloride, Dietary, Time Factors, Vasodilator Agents administration & dosage, Aldehyde Oxidoreductases antagonists & inhibitors, Antihypertensive Agents pharmacology, Endothelium, Vascular drug effects, Enzyme Inhibitors pharmacology, Femoral Artery drug effects, Hypertension drug therapy, Vasodilation drug effects, Vasodilator Agents pharmacology
- Abstract
Nitric oxide (NO) exerts a wide range of cellular effects in the cardiovascular system. NO is short lived, but S-nitrosoglutathione (GSNO) functions as a stable intracellular bioavailable NO pool. Accordingly, increased levels can facilitate NO-mediated processes, and conversely, catabolism of GSNO by the regulatory enzyme GSNO reductase (GSNOR) can impair these processes. Because dysregulated GSNOR can interfere with processes relevant to cardiovascular health, it follows that inhibition of GSNOR may be beneficial. However, the effect of GSNOR inhibition on vascular activity is unknown. To study the effects of GSNOR inhibition on endothelial function, we treated rats with a small-molecule inhibitor of GSNOR (N6338) that has vasodilatory effects on isolated aortic rings and assessed effects on arterial flow-mediated dilation (FMD), an NO-dependent process. GSNOR inhibition with a single intravenous dose of N6338 preserved FMD (15.3 ± 5.4 vs. 14.2 ± 6.3%, P = nonsignificant) under partial NO synthase inhibition that normally reduces FMD by roughly 50% (14.1 ± 2.9 vs. 7.6 ± 4.4%, P < 0.05). In hypertensive rats, daily oral administration of N6338 for 14 days reduced blood pressure (170.0 ± 5.3/122.7 ± 6.4 vs. 203.8 ± 1.9/143.7 ± 7.5 mmHg for vehicle, P < 0.001) and vascular resistance index (1.5 ± 0.4 vs. 3.2 ± 1.0 mmHg · min · l(-1) for vehicle, P < 0.001), and restored FMD from an initially impaired state (7.4 ± 1.7%, day 0) to a level (13.0 ± 3.1%, day 14, P < 0.001) similar to that observed in normotensive rats. N6338 also reversed the pathological kidney changes exhibited by the hypertensive rats. GSNOR inhibition preserves FMD under conditions of impaired NO production and protects against both microvascular and conduit artery dysfunction in a model of hypertension.
- Published
- 2013
- Full Text
- View/download PDF
116. Sca-1+ cardiosphere-derived cells are enriched for Isl1-expressing cardiac precursors and improve cardiac function after myocardial injury.
- Author
-
Ye J, Boyle A, Shih H, Sievers RE, Zhang Y, Prasad M, Su H, Zhou Y, Grossman W, Bernstein HS, and Yeghiazarians Y
- Subjects
- Animals, Apoptosis, Cell Differentiation, Cells, Cultured, Endothelial Cells metabolism, Flow Cytometry, Heart physiopathology, Immunohistochemistry, Leukocyte Common Antigens metabolism, Mice, Mice, Inbred C57BL, Mice, Transgenic, Myocardial Infarction physiopathology, Myocardial Ischemia metabolism, Myocardial Ischemia physiopathology, Myocardium pathology, Myocytes, Cardiac metabolism, Myocytes, Smooth Muscle metabolism, Neovascularization, Physiologic, Stem Cell Transplantation, Time Factors, Antigens, Ly metabolism, LIM-Homeodomain Proteins metabolism, Membrane Proteins metabolism, Myocardial Infarction metabolism, Myocardium metabolism, Stem Cells metabolism, Transcription Factors metabolism
- Abstract
Background: Endogenous cardiac progenitor cells are a promising option for cell-therapy for myocardial infarction (MI). However, obtaining adequate numbers of cardiac progenitors after MI remains a challenge. Cardiospheres (CSs) have been proposed to have cardiac regenerative properties; however, their cellular composition and how they may be influenced by the tissue milieu remains unclear., Methodology/principal Finding: Using "middle aged" mice as CSs donors, we found that acute MI induced a dramatic increase in the number of CSs in a mouse model of MI, and this increase was attenuated back to baseline over time. We also observed that CSs from post-MI hearts engrafted in ischemic myocardium induced angiogenesis and restored cardiac function. To determine the role of Sca-1(+)CD45(-) cells within CSs, we cloned these from single cell isolates. Expression of Islet-1 (Isl1) in Sca-1(+)CD45(-) cells from CSs was 3-fold higher than in whole CSs. Cloned Sca-1(+)CD45(-) cells had the ability to differentiate into cardiomyocytes, endothelial cells and smooth muscle cells in vitro. We also observed that cloned cells engrafted in ischemic myocardium induced angiogenesis, differentiated into endothelial and smooth muscle cells and improved cardiac function in post-MI hearts., Conclusions/significance: These studies demonstrate that cloned Sca-1(+)CD45(-) cells derived from CSs from infarcted "middle aged" hearts are enriched for second heart field (i.e., Isl-1(+)) precursors that give rise to both myocardial and vascular tissues, and may be an appropriate source of progenitor cells for autologous cell-therapy post-MI.
- Published
- 2012
- Full Text
- View/download PDF
117. Advanced Donor Age Impairs Bone Marrow Cell Therapeutic Efficacy for Cardiac Disease.
- Author
-
Wang X, Takagawa J, Haddad DJ, Pinnamaneni K, Zhang Y, Sievers RE, Grossman W, Yeghiazarians Y, and Springer ML
- Abstract
Therapeutic results of clinical autologous bone marrow cell (BMC) therapy trials for cardiac disease have been modest compared to results of BMC implantation into rodent hearts post-myocardial infarction (MI). In clinical trials, autologous BMCs are typically harvested from older patients who have recently suffered an MI. In contrast, experimental studies in rodent models typically utilize donor BMCs isolated from young, healthy, inbred mice that are not the recipients. Using unfractionated BMCs from donor mice at ages of young, middle-aged, and old, we discovered that recipient left ventricular function post-MI was significantly improved by young donor BMC implantation but was only preserved by middle-aged donor BMCs. Notably, old donor BMCs did not slow the decline in recipient post-MI cardiac function, suggesting BMC impairment by advanced donor age. Furthermore, we also show here that BMCs that are therapeutically impaired by donor age can be further impaired by concurrent donor MI. In conclusion, our findings suggest that therapeutic impairment of BMCs by advanced age is one of the important factors that can limit the success of clinical autologous BMC-based therapy.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.